RX STRENGTH AZELASTINE HCL 205.5 MCG IS OTC!
PRN NASAL SYMPTOM RELIEF THAT STARTS WORKING IN
Astepro® Allergy is different than INS sprays
- Starts working in 30 minutes1,8,† while INS sprays take hours to start to provide relief. Can take between 3 and 14 days to reach maximum efficacy levels2-7,‡
- Flexibility to dose PRN, once or twice a day, versus the leading allergy spray products that recommend daily dosing schedules that may not match patient usage behavior9,12,13,§
See how Astepro® compares with INS
ASTEPRO® OFFERS TRIPLE ADVANTAGES VS RX AZELASTINE (0.10%)
Strength:
OTC Astepro® offers the maximum strength azelastine HCl (0.15%), which means it has 50% higher concentration than azelastine 0.10%, which remains an Rx.9,16-18
Taste:
OTC Astepro® contains a sweetener to improve its taste profile versus the Rx 0.10% strength (the same improved taste profile as Rx Astepro® 0.15%).9,16,19
Duration:
OTC Astepro® offers nasal symptom relief for up to 24 hours, while the 0.10% Rx strength only has a 12-hour indication.9,18
Powerful, steroid-free nasal symptom relief for up to 24 hours9
- Relief of indoor and outdoor allergies of nasal congestion, runny nose, itchy nose, and sneezing, without steroids or an additional decongestant9
- The same as prescription Astepro® Allergy (azelastine HCl 205.5 mcg) nasal spray9,16-18
FDA approved for children age 6+
- Steroid-free relief of nasal allergy symptoms including congestion9
- Dosing as needed9,||
- Does not have a label warning regarding pediatric growth suppression9
INS, intranasal steroid.
*Compared with other steroid allergy sprays, on day 1.
†On day 1.
‡INS onset based on various product information; time to maximum efficacy depends on the INS brand.
§In a survey of allergy patients that included nasal spray users (n=732), 42% of patients said they administer their INS “some days and not others.”12
||Up to twice daily.
REFERENCES:
1. Hsu S-N, Stevens DA, Sajjad F, Salapatek AM. Onset of action of azelastine HCl nasal spray 0.15% evaluated in an environmental exposure chamber. Poster presented at: ACAAI Annual Scientific Meeting; November 10-14, 2022; Louisville, KY. 2. Flonase® website. Accessed June 13, 2023. https://www.flonase.com/faqs/ 3. Flonase®. Prescribing Information. GlaxoSmithKline; 2019. 4. Haleon Health Partner website. Accessed June 13, 2023. https://www.haleonhealthpartner.com/en-us/respiratory-health/brands/flonase-products/flonase/dosing-administration-flonase-allergy-relief/ 5. Nasacort® website. Accessed June 13, 2023. https://www.nasacort.com/allergy-nasal-spray 6. Nasacort® AQ. Prescribing information. Sanofi-aventis U.S. LLC; 2008. 7. Budesonide Nasal Spray. Prescribing information. Apotex Inc.; 2011. 8. Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(6):628-633. doi:10.2500/aap.2009.30.3296 9. NDA 213872. 10. FDA approves a nasal antihistamine for nonprescription use. Approval is a first-in-class and was enabled by the prescription to nonprescription switch process. News release. FDA; June 17, 2021. Accessed June 13, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-antihistamine-nonprescription-use 11. Data on file. Bayer. IRI data. Only OTC AH. 12. Data on file. Bayer. Habits and practices. 13. Ortiz G, Knudtson M. Counseling patients on the use of intransal steroids in allergic rhinitis management. Consultant. 2017;57(6):328-334. 14. Flonase® Drug Facts Label. NDA205434. 15. Nasacort® Drug Facts Label. NDA020468. 16. Astepro®. Prescribing information. Meda Pharmaceuticals Inc; 2018. 17. US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed June 13, 2023. 18. Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014. 19. van Bavel J, Howland WC, Amar NJ, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray administered once daily in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(5):512-518. doi:10.2500/aap.2009.30.3284